Section Arrow
EWTX.NASDAQ
- Edgewise Therapeutics
Quotes are at least 15-min delayed:2025/11/18 19:01 EST
After Hours
Last
 21.73
-0.43 (-1.94%)
Bid
21.6
Ask
24.96
High 22.16 
Low 21.73 
Volume 7902 
Regular Hours
Last
 22.16
-0.1 (-0.45%)
Day High 
22.73 
Prev. Close
22.26 
1-M High
24 
Volume 
1.04M 
Bid
21.6
Ask
24.96
Day Low
21.6 
Open
22.26 
1-M Low
14.675 
Market Cap 
2.36B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 19.53 
20-SMA 17.98 
50-SMA 16.26 
52-W High 35.5 
52-W Low 10.6 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.57/-2.00
Enterprise Value
2.36B
Balance Sheet
Book Value Per Share
5.28
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CANFCan-Fite BioPharma Ltd0.3801+0.0181+5.00%-- 
After Hours 0.4046 +0.0245 +6.45%
ASBPAspire Biopharma Holdings Inc.0.1057+0.0144+15.77%-- 
After Hours 0.104 -0.0017 -1.61%
OLMAOlema Pharmaceuticals20.14+11.62+136.38%-- 
After Hours 19.12 -1.02 -5.06%
CMNDClearmind Medicine0.2164-0.0605-21.85%0.16PE
After Hours 0.2311 +0.0147 +6.79%
APLTApplied Therapeutics0.2984+0.0142+5.00%-- 
After Hours 0.29 -0.0084 -2.82%
Quotes are at least 15-min delayed:2025/11/18 19:01 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.